BPC
SNDX icon

Bryce Point Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Bryce Point Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,109
Closed -$198K – 256
2025
Q2 		$198K Buy
+21,109
New +$232K 0.17% 152
2025
Q1 		– Sell
-31,565
Closed -$417K – 415
2024
Q4 		$417K Buy
+31,565
New +$540K 0.12% 381

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Bryce Point Capital's SNDX Position: Q3 2025 in Review

Bryce Point Capital sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 21,109 shares — an estimated $198K sold.

Bryce Point Capital first reported a position in SNDX in Q4 2024 and held it in 2 quarters. The position peaked at $417K in Q4 2024. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • Bryce Point Capital reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Bryce Point Capital sold 21,109 Syndax Pharmaceuticals shares in Q3 2025, an estimated $198K.
  • Bryce Point Capital first reported a position in Syndax Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Bryce Point Capital's Syndax Pharmaceuticals position peaked at $417K in Q4 2024.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.